Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in ...
Gilead Sciences reported positive Phase 3 results for Trodelvy in combination with Keytruda in first-line PD-L1+ metastatic ...
Gilead Sciences, Inc. (NASDAQ:GILD) is among the most profitable healthcare stocks to buy. On January 26, UBS lifted the ...
Zacks Investment Research on MSN
Gilead Sciences, Inc. (GILD) is attracting investor attention: Here is what you should know
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Gilead Sciences advances global biopharmaceutical research as part of broader healthcare activity linked to the nasdaq 100 ...
US biotech Gilead Sciences today announced that its Trodelvy (sacituzumab govitecan-hziy) has now been added to the National ...
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.
Gilead's Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise outperformance. Learn more about GILD stock here.
Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results